COMBAT COVID-19 - induced adult respiratory distress syndrome
- Funded by Innovationsfonden Denmark
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Innovationsfonden DenmarkPrincipal Investigator
N/A
Research Location
DenmarkLead Research Institution
Rigshospitalet, Nordsjællands Hospital Bispebjerg Hospital, Herlev Hospital, Hvidovre Hospital, BioPorto AS, Endothel Pharma ApResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
More than 50% of COVID-19 infected patients with acute lung failure and in need of respiratory therapy do not survive. This is due to damage to the body's smallest vessel (capillaries) and the severity of capillary damage can be measured with a biomarker called thrombomodulin (TM). Previous studies have shown that patients with severe organ failure (including lung failure) had a high level of TM and that this could be reduced by treatment with prostacylin (Iloprost). The project will test whether prostacyclin (Iloprost) improves lung function, thus reducing the need for respiratory therapy, in COVID-19 patients with acute lung failure and thus potentially increases survival.